Shortwave Life Sciences Plc is an incubation and pre-seed investment company, which engages in psychedelic science and healthcare industry. The firm has an interest in the emerging area of psychedelic-based drug development, where compounds are increasingly recognized and approved as having potential for treating mental health diseases and life-threatening conditions. The company focuses on clinical impact independent of treatment, enhances patient adherence and minimizes dose-dependent side effects. Its Anorexia program buccal film is fully developed and in clinical testing. The company is focused on developing formulations containing multiple active compounds to maximize therapeutic benefits. Its psilocybin-based application programming interface (API) combination for anorexia nervosa offers an expanded mechanism of action aimed at addressing multiple receptors in the patient’s brain. Its first program targets treatment-resistant Anorexia Nervosa, addressing a critical area of unmet medical need.